Immunovant Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Immunovant Inc 's ROA in the first quarter of 2026?
Immunovant Inc recorded a cumulative net loss of $-538 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -67.88%.

However, within the Healthcare sector 654 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4107, from total ROA ranking in the fourth quarter of 2026 at 4756.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Total Assets Change	28.88 %	23.65 %	16.49 %	13.04 %	12.17 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-538	-506	-464	-465	-447
Return On Assets (TTM)	-67.88 %	-67.86 %	-66.39 %	-69.18 %	-68.3 %
IMVT's Total Ranking	# 4107	# 4756	# 4199	# 4258	# 4315
Total Assets (TTM) in million	852	960	776	583	661
Seq. Total Assets Change	-11.18 %	23.65 %	33.15 %	-11.87 %	-14.79 %
Seq. Net Income Change	-	-	-	-	-

IMVT's 5 Years Annual ROA >> Back to IMVT Management Effectiveness >> Compare IMVT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 95
Sector	# 655
Overall	# 4071

Return On Assets Statistics
High	Average	Low
-0 %	-52.28 %	-85.94 %
		(Mar 31 2020)

Financial Statements
Immunovant Inc 's Assets	$ 852 million	IMVT's Balance sheet
Immunovant Inc 's Income	$ -153 million	Quarterly IMVT's Income Statement
IMVT's Income by Division		See IMVT's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022
Y / Y Total Assets Change	23.29 %	16.49 %	64.26 %	-21.32 %	25.07 %
Total Assets in million	957	776	666	406	516
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-506	-414	-259	-211	-157
Annual Return On Assets	-52.83 %	-53.31 %	-38.92 %	-52 %	-30.4 %

IMVT's 5 Years Annual ROA >> Back to IMVT Management Effectiveness >> Compare IMVT ROA to its Competitors

More Return On Assets Ratios
IMVT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IMVT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IMVT's Competitors
Subscribers only: Roa for Immunovant Inc 's Suppliers
Subscribers only: Return On Assets for IMVT's Customers

You may also want to know
IMVT's Roi	IMVT's Inventory Turnover Ratio	IMVT's Growth Rates	IMVT's Dividend Comparisons
	IMVT's Profitability Ratios	IMVT's Asset Turnover Ratio	IMVT's Dividend Growth
IMVT's Roe	IMVT's Valuation Ratios	IMVT's Financial Strength Ratios	IMVT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T18:14:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.